The study aimed to investigate the effectiveness and safety of hydrogen inhalation therapy (HI) as an adjunct treatment for Chinese patients with type 2 diabetes mellitus (T2DM) in a real-life clinical setting.
The research was conducted retrospectively and non-interventionally over a period of 6 months. The study included T2DM patients who were receiving conventional anti-diabetes medication with or without HI from 2018 to 2021.
Patients were assigned to either the HI group or the control group after propensity score matching. The mean change in glycated hemoglobin (HbA1c) after 6 months was evaluated as the primary outcome, while the secondary outcome included the mean change of fasting plasma glucose (FPG), weight, lipid profile, and homeostasis model assessment. In total, 1088 patients were included in the analysis, and the results showed that patients in the HI group maintained greater improvement in HbA1c, FPG, total cholesterol, HOMA-IR, and HOMA-β compared to the control group.
Furthermore, the likelihood of reaching different HbA1c levels after 6 months of treatment was higher in the HI group. In terms of safety, patients in the HI group had a lower incidence of adverse events such as hypoglycemia, vomiting, constipation, and giddiness compared to the control group.
Overall, the study concluded that HI therapy as an adjunct treatment can effectively improve glycemic control, lipid metabolism, insulin resistance, and reduce adverse events in Chinese patients with T2DM after 6 months of treatment. These findings may inspire new approaches to the clinical treatment of diabetes.
Source from: https://pubmed.ncbi.nlm.nih.gov/36743938/
Comments